{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Wu W"],"pubmed_abstract":["<h4>Introduction</h4>This retrospective study aimed to investigate treatment patterns and outcomes in patients with NSCLC harboring EGFR20ins in China. EGFR20ins mutations are associated with poor responses to EGFR-TKIs, and limited real-world data exist regarding the efficacy of various treatment modalities.<h4>Methods</h4>In this retrospective, single-center study, treatment outcomes, including PFS and ORR, were evaluated for different treatment regimens based on imaging assessments. The impact of mutation heterogeneity on treatment efficacy was also explored.<h4>Results</h4>Data from 302 patients diagnosed with NSCLC with EGFR20ins were analyzed. EGFR-TKI monotherapy demonstrated suboptimal PFS compared to platinum-based chemotherapy in the first-line setting (3.00 m vs. 6.83 m, HR = 3."],"journal":["BMC cancer"],"pagination":["1010"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11323489"],"repository":["biostudies-literature"],"pubmed_title":["Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study."],"pmcid":["PMC11323489"],"pubmed_authors":["Yu S","Huang J","Dong J","Wu W","Wu Y","Qi Q"],"additional_accession":[]},"is_claimable":false,"name":"Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study.","description":"<h4>Introduction</h4>This retrospective study aimed to investigate treatment patterns and outcomes in patients with NSCLC harboring EGFR20ins in China. EGFR20ins mutations are associated with poor responses to EGFR-TKIs, and limited real-world data exist regarding the efficacy of various treatment modalities.<h4>Methods</h4>In this retrospective, single-center study, treatment outcomes, including PFS and ORR, were evaluated for different treatment regimens based on imaging assessments. The impact of mutation heterogeneity on treatment efficacy was also explored.<h4>Results</h4>Data from 302 patients diagnosed with NSCLC with EGFR20ins were analyzed. EGFR-TKI monotherapy demonstrated suboptimal PFS compared to platinum-based chemotherapy in the first-line setting (3.00 m vs. 6.83 m, HR = 3.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-19T20:40:33.168Z","creation":"2025-04-19T20:40:33.168Z"},"accession":"S-EPMC11323489","cross_references":{"pubmed":["39143560"],"doi":["10.1186/s12885-024-12773-x"]}}